<DOC>
	<DOCNO>NCT01501708</DOCNO>
	<brief_summary>In prospective phase II observational study , plan assess efficacy tolerability caspofungin base combine anti-fungal therapy proven probable IFI group patient receive allo-HSCT transplantation high risk IFI : HLA match unrelated donor mismatch donor conditioning ATG contain regimen present III-IV aGVHD extensive GVHD undergo high-dose steroid treatment .</brief_summary>
	<brief_title>Caspofungin Based Combined Anti-fungal Therapy Proven Probable Invasive Fungal Infection</brief_title>
	<detailed_description>Patients recieve caspofungin either voriconazole amphotericin B combination therapy fungal infection</detailed_description>
	<mesh_term>Mycoses</mesh_term>
	<mesh_term>Voriconazole</mesh_term>
	<mesh_term>Amphotericin B</mesh_term>
	<mesh_term>Liposomal amphotericin B</mesh_term>
	<mesh_term>Caspofungin</mesh_term>
	<mesh_term>Echinocandins</mesh_term>
	<mesh_term>Antifungal Agents</mesh_term>
	<mesh_term>Miconazole</mesh_term>
	<criteria>adult patient undergo allogeneic hematopoietic stem cell transplantation age 1855 year inform consent contraindication allogeneic transplantation : active infection , allergy FLu/Bu/CTX , liver renal function damage HLA mismatch relate ( 3~5/6 ) unrelated donor ( least 8/10 ) proven probable IFI age less 18 year 56 year HLA mismatch related donor liver function/renal function damage ( 2 X upper normal range ) mental disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>caspofungin</keyword>
	<keyword>IFI</keyword>
	<keyword>allogeneic hematopoietic stem cell transplantation</keyword>
</DOC>